Phelan Robert J.
Known title: Chief Financial OfficerCIK: 0001802419
Associated companies
Transaction History
| CVSA | ▼ Sell | Tax Withholding | 1,279 | $169K | 8/23/2026 | View on chart |
| CVSA | ▲ Buy | Grant | 7,056 | $934K | 8/23/2026 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 3,126 | $414K | 8/23/2026 | View on chart |
| CVSA | ▲ Buy | Grant | 10,080 | $1.3M | 8/23/2026 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 4,466 | $591K | 8/23/2026 | View on chart |
| CVSA | ▼ Sell | Open Market | 2,186 | $295K | 8/7/2026 | View on chart |
| CVSA | ▼ Sell | Open Market | 2,414 | $327K | 7/8/2026 | View on chart |
| CVSA | ▼ Sell | Open Market | 2,900 | $393K | 7/7/2026 | View on chart |
| CVSA | ▼ Sell | Open Market | 10,000 | $1.3M | 5/8/2026 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 623 | $60K | 11/13/2025 | View on chart |
| CVSA | ▲ Buy | Grant | 4,259 | $413K | 11/12/2025 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 1,637 | $156K | 11/10/2025 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 173 | $23K | 8/25/2025 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 1,414 | $191K | 8/24/2025 | View on chart |
| CVSA | ▲ Buy | Grant | 19,305 | $2.6M | 8/24/2025 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 8,553 | $1.2M | 8/24/2025 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 9,537 | $1.3M | 8/23/2025 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 1,279 | $173K | 8/23/2025 | View on chart |
| CVSA | ▲ Buy | Grant | 21,555 | $2.9M | 8/23/2025 | View on chart |
| CVSA | ▲ Buy | Grant | 4,220 | $379K | 11/13/2024 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 1,622 | $148K | 11/10/2024 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 186 | $14K | 8/26/2024 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 173 | $13K | 8/25/2024 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 442 | $33K | 8/25/2024 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 342 | $26K | 8/25/2024 | View on chart |
| CVSA | ▲ Buy | Grant | 997 | $75K | 8/25/2024 | View on chart |
| CVSA | ▲ Buy | Grant | 770 | $58K | 8/25/2024 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 1,427 | $108K | 8/24/2024 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 1,257 | $95K | 8/23/2024 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 1,567 | $102K | 5/12/2024 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 1,056 | $59K | 11/10/2023 | View on chart |
| CVSA | ▲ Buy | Grant | 672 | $29K | 8/26/2023 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 197 | $9K | 8/26/2023 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 123 | $5K | 8/26/2023 | View on chart |
| CVSA | ▲ Buy | Grant | 718 | $31K | 8/26/2023 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 204 | $9K | 8/26/2023 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 111 | $5K | 8/25/2023 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 915 | $40K | 8/24/2023 | View on chart |
| CVSA | ▲ Buy | Grant | 8,660 | $372K | 8/23/2023 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 992 | $40K | 2/12/2023 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 1,050 | $45K | 11/10/2022 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 119 | $5K | 8/26/2022 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 111 | $5K | 8/25/2022 | View on chart |
| CVSA | ▲ Buy | Grant | 9,660 | $384K | 8/24/2022 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 1,012 | $24K | 2/14/2022 | View on chart |
| CVSA | ▲ Buy | Grant | 14,780 | $500K | 11/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Covista receives mixed analyst coverage and rating update
Recent commentary on Covista is mixed. ChartMill describes the stock as a GARP case with reasonable growth and valuation. Yahoo published both a target‑focused piece and a separate article highlighting reasons to avoid the stock. BMO Capital kept an Outperform rating but lowered its price target to $145.
Covista receives mixed analyst coverage and rating update. Recent commentary on Covista is mixed. ChartMill describes the stock as a GARP case with reasonable growth and valuation. Yahoo published both a target‑focused piece and a separate article highlighting reasons to avoid the stock. BMO Capital kept an Outperform rating but lowered its price target to $145.